Aldosterone Blockade Reduces Mortality without Changing Cardiac Remodeling in Spontaneously Hypertensive Rats
Open Access
- 1 January 2013
- journal article
- research article
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 32 (5), 1275-1287
- https://doi.org/10.1159/000354526
Abstract
Background: The role of aldosterone blockers during transition from long-term compensated hypertrophy to dilated failure is not completely understood. In this study we evaluated the effects of early administration of spironolactone on cardiac remodeling, myocardial function, and mortality in spontaneously hypertensive rats (SHR). Methods: Sixteen-month-old SHR received no treatment (SHR-C, n=72) or spironolactone (SHR-SPR, 20 mg/kg/day, n=34) for six months. Echocardiogram was performed before and after treatment. Myocardial function was analyzed in left ventricular (LV) papillary muscle preparations. Myocardial collagen aund hydroxyproline concentration were evaluated by morphometry and spectrophotometry, respectively. LV gene expression was assessed by real time RT-PCR. Statistics: Student's t test; Log rank test (Kaplan Meyer). Results: SHR-C and SHR-SPR presented mortality rates of 71 and 38%, respectively (p=0.004). Systolic arterial pressure did not differ between groups (SHR-C 199 +/- 43; SHR-SPR 200 +/- 35 mmHg). Initial and final echocardiograms did not show significant differences in cardiac structures or LV function between groups. Myocardial function was similar between groups at basal and after inotropic stimulation. Collagen fractional area, hydroxyproline concentration, gene expression for alpha- and beta-myosin heavy chain, atrial natriuretic peptide, and Serca2a were not different between groups. Conclusion: Early spironolactone administration reduces mortality without changing cardiac remodeling in spontaneous hypertensive rats. Copyright (C) 2013 S. Karger AG, BaselThis publication has 45 references indexed in Scilit:
- Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection FractionJAMA, 2013
- Aldosterone in Heart DiseaseCurrent Hypertension Reports, 2012
- Effect of Spironolactone on Left Ventricular Ejection Fraction and Volumes in Patients With Class I or II Heart FailureThe American Journal of Cardiology, 2010
- Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failureHeart Rhythm, 2009
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytesCardiovascular Research, 2005
- Myocardial Dysfunction Induced by Food Restriction is Related to Morphological Damage in Normotensive Middle-Aged RatsJournal of Biomedical Science, 2005
- Aldosterone directly stimulates cardiac myocyte hypertrophyJournal of Cardiac Failure, 2004
- Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarctionJournal of Cardiac Failure, 2004
- Review of aldosterone- and angiotensin II-induced target organ damage and preventionCardiovascular Research, 2004